Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Extracellular vesicle proteome unveils cathepsin B connection to Alzheimer’s disease pathogenesis

Open access

Abstract

Extracellular vesicles (EVs) are membrane vesicles that are released extracellularly and considered to be implicated in the pathogenesis of neurodegenerative diseases including Alzheimer’s disease. Here, CSF EVs of 16 ATN-classified cases were subjected to quantitative proteome analysis. In these CSF EVs, levels of 11 proteins were significantly altered during the ATN stage transitions (P < 0.05 and fold-change > 2.0). These proteins were thought to be associated with Alzheimer’s disease pathogenesis and represent candidate biomarkers for pathogenic stage classification. Enzyme-linked immunosorbent assay analysis of CSF and plasma EVs revealed altered levels of cathepsin B (CatB) during the ATN transition (seven ATN groups in validation set, n = 136). The CSF and plasma EV CatB levels showed a negative correlation with CSF amyloid-β42 concentrations. This proteomic landscape of CSF EVs in ATN classifications can depict the molecular framework of Alzheimer’s disease progression, and CatB may be considered a promising candidate biomarker and therapeutic target in Alzheimer’s disease amyloid pathology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awad361

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Workflow of the analysis of extracellular vesicle (EV) proteins in CSF and plasma according to ATN classification. CSF and plasma samples were collected from normal control (NC), mild cognitive impairment (MCI), and Alzheimer’s disease (AD) participants and classified into ATN groups based on the levels of Aβ42, pTau and tTau in the CSF. In the liquid chromatography-mass spectrometry-based biomarker discovery phase, after the exclusion of non-AD pathologic changes, EVs were isolated from the 16 selected CSF samples using size exclusion chromatography and analysed by mass spectrometry. In an enzyme-linked immunosorbent assay (ELISA)-based validation study for CatB, EVs were collected from 136 CSF and plasma samples by ultracentrifugation prior to the ELISA. LC-MS/MS= liquid chromatography-tandem mass spectrometry; ROC = receiver operating characteristic.
Figure 1 Workflow of the analysis of extracellular vesicle (EV) proteins in CSF and plasma according to ATN classification. CSF and plasma samples were collected from normal control (NC), mild cognitive impairment (MCI), and Alzheimer’s disease (AD) participants and classified into ATN groups based on the levels of Aβ42, pTau and tTau in the CSF. In the liquid chromatography-mass spectrometry-based biomarker discovery phase, after the exclusion of non-AD pathologic changes, EVs were isolated from the 16 selected CSF samples using size exclusion chromatography and analysed by mass spectrometry. In an enzyme-linked immunosorbent assay (ELISA)-based validation study for CatB, EVs were collected from 136 CSF and plasma samples by ultracentrifugation prior to the ELISA. LC-MS/MS= liquid chromatography-tandem mass spectrometry; ROC = receiver operating characteristic.CC BY · PubMed Central
Figure 2 Proteomic analysis of CSF extracellular vesicle (EV) proteins in the discovery set under ATN classification. (A) Venn diagram of CSF EV proteins quantified in three ATN groups. (B and C) Volcano plots showing statistically significant EV proteins in A+T−N−/A+T−N+ versus A−T−N− (B) and in A+T+N+ versus A+T−N−/A+T−N+ (C). (D) The abundances of CatB protein quantified by mass spectrometry are shown. A = Aβ deposition; N = neurodegeneration; nd = not detected; T = pathological tau.
Figure 2 Proteomic analysis of CSF extracellular vesicle (EV) proteins in the discovery set under ATN classification. (A) Venn diagram of CSF EV proteins quantified in three ATN groups. (B and C) Volcano plots showing statistically significant EV proteins in A+T−N−/A+T−N+ versus A−T−N− (B) and in A+T+N+ versus A+T−N−/A+T−N+ (C). (D) The abundances of CatB protein quantified by mass spectrometry are shown. A = Aβ deposition; N = neurodegeneration; nd = not detected; T = pathological tau.CC BY · PubMed Central
Figure 3 ELISA-based validation of CatB in CSF extracellular vesicles (EVs). (A) Box plots of CatB abundances in CSF EVs in each ATN group, which were quantified by ELISA (validation set, n = 136). (B) Box plots of CatB in CSF EVs in A+/A−, T+/T and N+/N− classifications. One-way ANOVA, followed by Tukey’s multiple comparisons test. ns = non-significant, **P < 0.01, ***P < 0.005. (C–E) Scatter plots showing correlations between CatB in CSF EVs and (C) Aβ42, (D) pTau and (E) total Tau levels in CSF. AD = Alzheimer’s disease; Aβ = amyloid beta; A = Aβ deposition; N = neurodegeneration; T = pathological tau.
Figure 3 ELISA-based validation of CatB in CSF extracellular vesicles (EVs). (A) Box plots of CatB abundances in CSF EVs in each ATN group, which were quantified by ELISA (validation set, n = 136). (B) Box plots of CatB in CSF EVs in A+/A−, T+/T and N+/N− classifications. One-way ANOVA, followed by Tukey’s multiple comparisons test. ns = non-significant, **P < 0.01, ***P < 0.005. (C–E) Scatter plots showing correlations between CatB in CSF EVs and (C) Aβ42, (D) pTau and (E) total Tau levels in CSF. AD = Alzheimer’s disease; Aβ = amyloid beta; A = Aβ deposition; N = neurodegeneration; T = pathological tau.CC BY · PubMed Central
Figure 4 ELISA validation of CatB in plasma extracellular vesicles (EVs) as a putative blood biomarker using ATN classification. (A) Box plots of CatB abundances in plasma EVs in each ATN group, which were quantified by ELISA (validation set, n = 136). (B) Box plots of plasma-EV-CatB in A+/A−, T+/T− and N+/N− classifications. One-way ANOVA, followed by Tukey’s multiple comparisons test. ns = non-significant, *P < 0.05 and ***P < 0.005. (C) Correlations between CatB levels in EVs derived from CSF and plasma. (D–F) Scatter plots showing correlations between plasma-EV-CatB and (D) Aβ42, (E) pTau and (F) total Tau levels in CSF. A = Aβ deposition; AD = Alzheimer’s disease; N = neurodegeneration; T = pathological tau.
Figure 4 ELISA validation of CatB in plasma extracellular vesicles (EVs) as a putative blood biomarker using ATN classification. (A) Box plots of CatB abundances in plasma EVs in each ATN group, which were quantified by ELISA (validation set, n = 136). (B) Box plots of plasma-EV-CatB in A+/A−, T+/T− and N+/N− classifications. One-way ANOVA, followed by Tukey’s multiple comparisons test. ns = non-significant, *P < 0.05 and ***P < 0.005. (C) Correlations between CatB levels in EVs derived from CSF and plasma. (D–F) Scatter plots showing correlations between plasma-EV-CatB and (D) Aβ42, (E) pTau and (F) total Tau levels in CSF. A = Aβ deposition; AD = Alzheimer’s disease; N = neurodegeneration; T = pathological tau.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Cited by

See all 47

Metadata

Authors
Yuyama, K., Sun, H., Fujii, R., Hemmi, I., Ueda, K., & Igeta, Y.
Affiliations
  • Hokkaido University (JP)
  • Japanese Foundation For Cancer Research (JP)
  • Japanese Red Cross College of Nursing (JP)
  • Toranomon Hospital (JP)
Corresponding author
Igeta, Yukifusa
Venue
Brain
Published
2023-12-10
Volume
147
Issue
2
Pages
627-636
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W4389522425
Cited by
47
References
54
Citations by year
2026: 15 · 2025: 25 · 2024: 7
FWCI
4.18
Type
journal article
Language
en
Open access
Locations
  • Brain (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • KAKENHI (22K07341)
  • Japan Society for the Promotion of Science
  • Okinaka Memorial Foundation
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
extracellular vesicles, cathepsin B, Alzheimer's disease, amyloid-beta 42, cerebrospinal fluid, plasma extracellular vesicles, biomarkers, proteome, amyloid pathology, therapeutic target
MeSH terms
Extracellular Vesicles, Alzheimer Disease, Cathepsin B, Humans, Biomarkers, Amyloid beta-Peptides, tau Proteins, Proteome, Proteomics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Extracellular vesicle proteome unveils cathepsin B connection to Alzheimer’s disease pathogenesis. https://app.cochat.ai/papers/10.1093/brain/awad361
The paper
Yuyama, K., Sun, H., Fujii, R., Hemmi, I., Ueda, K., & Igeta, Y. (2024). Extracellular vesicle proteome unveils cathepsin B connection to Alzheimer’s disease pathogenesis. Brain. https://doi.org/10.1093/brain/awad361

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.